title: Cost effectiveness in obstetrics and gynecology: The levonorgestrel intrauterine system.
abstract: Use of evidence-based practices that are both cost-effective and acceptable to patients is now a focus in health care. Considerable cost savings can be realized by reducing unintended pregnancies and improving control of menstrual-related morbidity. The levonorgestrel intrauterine system (LNG-IUS), often referred to by its brand name Mirena, has been approved by the Food and Drug Administration both for contraception and fortreating abnormal uterine bleeding. The device has been available in the United States since 2000 and has been used in Europe since 1990. Despite the fact that several evidence-based guidelines include use of the LNG-IUS, it remains underutilized in this country. This article reviews the benefits of the LNG-IUS as they pertain to women's health and to the cost of health care.
authors.affiliation: Alina Medical Clinic, Fridley, USA.
authors.forename: Lisa
authors.initials: L
authors.lastname: Mattson
mesh_terms: D003271:Contraceptive Agents, Female / Q000191:economics*; D003362:Cost-Benefit Analysis; D019317:Evidence-Based Medicine / Q000191:economics*; D005260:Female; D006176:Gynecology / Q000191:economics*; D006801:Humans; D007436:Intrauterine Devices, Medicated / Q000191:economics*; D016912:Levonorgestrel / Q000191:economics*; D008910:Minnesota; D009774:Obstetrics / Q000191:economics*
chemical_list: D003271:Contraceptive Agents, Female; D016912:Levonorgestrel